<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023994</url>
  </required_header>
  <id_info>
    <org_study_id>BP41192</org_study_id>
    <nct_id>NCT04023994</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants</brief_title>
  <official_title>A Single-Center, Randomized, Adaptive, Investigator/Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to
      investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending
      intravenous (IV) doses of RO7126209 in healthy participants. RO7126209 is being developed for
      the treatment of Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a parallel group design, with participants recruited in 5 planned sequential
      cohorts. Additional cohort(s) may be added if dose escalation stopping criteria are not met
      after cohort 5. Participants will receive a single IV dose of either RO7126209 or placebo.
      RO7126209 doses will be administered in ascending order. After the starting dose, subsequent
      doses will be selected in an adaptive manner during study conduct based on emerging safety,
      tolerability and PK data.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 3, 2019</start_date>
  <completion_date type="Anticipated">August 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to approximately 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Laboratory Findings</measure>
    <time_frame>Up to approximately 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Vital Signs and Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Up to approximately 57 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration at the End of Infusion (Cend) of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209</measure>
    <time_frame>Days 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (T1/2) of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance Calculated as Dose/AUC (CL) of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady-State (V) of RO7126209</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral spinal fluid (CSF) Concentration of RO7126209</measure>
    <time_frame>Baseline, Day 3 or Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-RO7126209 Antibodies (ADAs)</measure>
    <time_frame>Days 1, 8, 29, and 57</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Alzheimers Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose level 1 of RO7126209 and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single intravenous dose level 1 of RO7126209 or matching placebo as per schedule specified in the respective arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose level 2 of RO7126209 and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single intravenous dose level 2 of RO7126209 or matching placebo as per schedule specified in the respective arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose level 3 of RO7126209 and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single intravenous dose level 3 of RO7126209 or matching placebo as per schedule specified in the respective arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Dose level 4 of RO7126209 and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single intravenous dose level 4 of RO7126209 or matching placebo as per schedule specified in the respective arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Dose level 5 of RO7126209 and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single intravenous dose level 5 of RO7126209 or matching placebo as per schedule specified in the respective arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7126209</intervention_name>
    <description>Participants will be administered a single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.</description>
    <arm_group_label>Cohort 1: Dose level 1 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 2: Dose level 2 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 3: Dose level 3 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 4: Dose level 4 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 5: Dose level 5 of RO7126209 and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be administered a single intravenous dose of matching placebo.</description>
    <arm_group_label>Cohort 1: Dose level 1 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 2: Dose level 2 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 3: Dose level 3 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 4: Dose level 4 of RO7126209 and placebo</arm_group_label>
    <arm_group_label>Cohort 5: Dose level 5 of RO7126209 and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy status is defined by the absence of evidence of any active or chronic disease
             following a detailed medical and surgical history, a complete physical examination
             including vital signs, 12-lead ECG, ophthalmologic examination, hematology, blood
             chemistry, coagulation, serology, and urinalysis.

          -  Body mass index (BMI) of 18-30 kg/m2 inclusive

          -  During the treatment period and until the final follow up visit, agreement to: (1)
             Remain abstinent or use contraceptive measures such as a condom plus an additional
             contraceptive method that together result in a failure rate of &lt;1% per year, with a
             partner who is a woman of childbearing potential. (2) With pregnant female partner,
             remain abstinent or use contraceptive measures such as a condom to avoid exposing the
             embryo. (3) Refrain from donating sperm from Day 1 of the study until 90 days after
             last dose.

        Exclusion Criteria:

          -  Concomitant disease or condition that could interfere with, or treatment of which
             might interfere with, the conduct of the study, or that would, in the opinion of the
             Investigator, pose an unacceptable risk to the participant in this study.

          -  History of any clinically significant gastrointestinal, renal, hepatic,
             broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,
             ophthalmologic, hematological or allergic disease, metabolic disorder, cancer or
             cirrhosis.

          -  Any suspicion or history of alcohol abuse and/or suspicion of regular consumption of
             drug of abuse within the last 5 years.

          -  Positive result on hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency
             virus (HIV) 1 and 2.

          -  History or presence of clinically significant ECG abnormalities or cardiovascular
             disease.

          -  Clinically-significant abnormalities in laboratory test results.

          -  Any major illness within one month before the screening examination or any febrile
             illness within one week prior to screening and up to first dose administration.

          -  Impaired hepatic function as indicated by screening aspartate aminotransferase (AST)
             or alanine aminotransferase (ALT) &gt;=1.5 x the upper limit of normal (ULN) or abnormal
             total bilirubin unless due to Gilbert's disease.

          -  Any clinically relevant history of hypersensitivity or allergic reactions, either
             spontaneous or following drug administration, or exposure to foods or environmental
             agents.

          -  History of hypersensitivity to biologic agents or any of the excipients in the
             formulation.

          -  History of raised intra-cerebral pressure or vertebral joint pathology

          -  Use of prohibited medication or herbal remedies as described in the section of
             concomitant medications

          -  Prior administration of gantenerumab (RO4909832)

          -  Any vaccination within two months prior to Day 1

          -  Participation in an investigational drug medicinal product or medical device study
             within 30 days before screening or within seven times the elimination half-life if
             known, whichever is longer.

          -  Participants who regularly smoke more than 5 cigarettes daily or equivalent and are
             unable or unwilling not to smoke during the in-house period.

          -  Donation or loss of blood over 500 mL within three months prior to Day 1 and donation
             of blood for the duration of the study until follow-up.

          -  Evidence of clinically significant brain magnetic resonance imaging (MRI) findings,
             including lacunar infarct, territorial infarct or macroscopic hemorrhage, microbleed
             or area of leptomeningeal hemosiderosis, or deep white matter lesions corresponding to
             an overall Fazekas score of â‰¥ 2.

          -  Claustrophobia, presence of pacemakers, aneurysm clips, artificial heart valves, ear
             implants, or foreign metal objects in the eyes, skin, or body that would
             contraindicate an MRI scan.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

